Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher G Twitty

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Oncology Reports|February 13, 2020
Prognostic Biomarkers for Melanoma ImmunotherapyChristopher G Twitty, Laura A Huppert, Adil I Daud
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2011
Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanismChristopher G Twitty, Shawn M Jensen, Hong-Ming Hu, et al.
Cancer Journal (Sudbury, Mass.)|September 29, 2011
Multiple vaccinations: friend or foeSarah E Church, Shawn M Jensen, Christopher G Twitty, et al.
Molecular Therapy. Nucleic Acids|March 23, 2017
Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In VitroAmy H Lin, Christopher G Twitty, Ryan Burnett, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 23, 2012
Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrenceShawn M Jensen, Christopher G Twitty, Levi D Maston, et al.
Cancer Immunology Research|December 20, 2019
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell ResponsesSamantha K Greaney, Alain P Algazi, Katy K Tsai, et al.
Molecular Therapy Oncolytics|May 20, 2022
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunityJack Y Lee, Bianca Nguyen, Anandaroop Mukhopadhyay, et al.
Molecular Cancer Research : MCR|March 18, 2022
Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor ImmunityMia Han, Bianca Nguyen, Jack Y Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2019
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell CarcinomaShailender Bhatia, Natalie V Longino, Natalie J Miller, et al.
Immunity|September 14, 2022
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Oncology Reports|February 13, 2020
Prognostic Biomarkers for Melanoma ImmunotherapyChristopher G Twitty, Laura A Huppert, Adil I Daud
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2011
Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanismChristopher G Twitty, Shawn M Jensen, Hong-Ming Hu, et al.
Cancer Journal (Sudbury, Mass.)|September 29, 2011
Multiple vaccinations: friend or foeSarah E Church, Shawn M Jensen, Christopher G Twitty, et al.
Molecular Therapy. Nucleic Acids|March 23, 2017
Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In VitroAmy H Lin, Christopher G Twitty, Ryan Burnett, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 23, 2012
Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrenceShawn M Jensen, Christopher G Twitty, Levi D Maston, et al.
Cancer Immunology Research|December 20, 2019
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell ResponsesSamantha K Greaney, Alain P Algazi, Katy K Tsai, et al.
Molecular Therapy Oncolytics|May 20, 2022
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunityJack Y Lee, Bianca Nguyen, Anandaroop Mukhopadhyay, et al.
Molecular Cancer Research : MCR|March 18, 2022
Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor ImmunityMia Han, Bianca Nguyen, Jack Y Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2019
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell CarcinomaShailender Bhatia, Natalie V Longino, Natalie J Miller, et al.
Immunity|September 14, 2022
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Pageof 2